PRPH_OUT_1 [2025-03-24 15:45:36 -0400] 2077 Bytes | 569 tokens | Cum: 569 tkns (7.11% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 3:45:35 PM on Mon Mar 24, 2025 -0400, and I'm firing up the spotlight on ProPhase Labs (PRPH), moving from 0.3088 to 0.4313. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for ProPhase Labs:

C1 - Mar-18-25 03:30PM - Q1 Virtual Investor Summit: On-Demand Presentations Now Live
C2 - Mar-07-25 08:00AM - ProPhase Labs to Present at the Investor Summit Virtual on March 11
C3 - Mar-05-25 09:55AM - Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now
C4 - Feb-26-25 08:00AM - Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
C5 - Feb-25-25 08:00AM - ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs
C6 - Feb-20-25 08:00AM - ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables
C7 - Feb-18-25 08:00AM - ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports
C8 - Jan-22-25 08:00AM - ProPhase Labs Announces Closing of $23.6 Million Sale of Pharmaloz Manufacturing to Houston-Based Private Equity Firm

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on ProPhase Labs (PRPH)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PRPH_OUT_3 [2025-03-24 15:45:39 -0400] 1038 Bytes | 248 tokens | Cum: 819 tkns (10.24% of 8k)
==========================================================================

Showing C3 (chunk 1 of 5): C3:
**Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now**
Date: Mar-05-25 09:55AM
Source: (Zacks)
URL: https://finance.yahoo.com/news/bears-losing-control-over-prophase-145506559.html

Shares ofProPhase Labs, Inc.(PRPH) have been struggling lately and have lost 21% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.

While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this company is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.

This is one of the popular price patterns in candlest

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PRPH_OUT_5 [2025-03-24 15:45:40 -0400] 923 Bytes | 267 tokens | Cum: 1088 tkns (13.60% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-24T12:10:50Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session - Capstone Holding (NASDAQ:CAPS), Allari...
A2 - 2025-03-21T10:49:49Z - North American Morning Briefing : Stock Futures Fall as Focus Shifts From Fed to Tariffs...
A3 - 2025-03-18T20:00:20Z - Investor Summit Group: Q1 Virtual Investor Summit: On-Demand Presentations Now Live...
A4 - 2025-03-18T19:33:02Z - Q1 Virtual Investor Summit: On-Demand Presentations Now Live...
A5 - 2025-03-14T10:41:42Z - North American Morning Briefing : Stock Futures -2-...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PRPH_OUT_7 [2025-03-24 15:45:42 -0400] 1038 Bytes | 308 tokens | Cum: 1398 tkns (17.47% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Monday's Pre-Market Session - Capstone Holding (NASDAQ:CAPS), Allarity Therapeutics (NASDAQ:ALLR)**Date: 2025-03-24Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44455940/12-health-care-stocks-moving-in-mondays-pre-market-sessionGainers Windtree Therapeutics WINT stock increased by 39.2% to $2.06 during Monday's pre-market session. The market value of their outstanding shares is at $1.5 million. Allarity Therapeutics ALLR shares moved upwards by 20.2% to $1.19. The market value of their outstanding shares is at $5.2 million. Capstone Holding CAPS stock rose 19.18% to $2.05. The market value of their outstanding shares is at $2.8 million. Tharimmune THAR shares rose 17.94% to $1.7. The market value of their outstanding shares is at $3.2 million. Regencell Bioscience RGC share

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PRPH_OUT_9 [2025-03-24 15:45:43 -0400] 1034 Bytes | 311 tokens | Cum: 1711 tkns (21.39% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-11-08T04:37:00Z - ProPhase Labs Announces Pricing of Public Offering of Common Stock
B2 - 2024-08-07T13:01:00Z - Antibody Production Market to Surpass USD 36.49 Billion by 2032 Driven by Escalating Demand for Targeted Therapies and Technological Advancements | Research by SNS Insider
B3 - 2024-06-06T12:00:00Z - Rare Stock Picks In May 2024 - From 29 Discerning Analysts
B4 - 2024-05-09T19:40:00Z - ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated
B5 - 2024-05-07T12:10:10Z - Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
B6 - 2024-05-06T21:10:03Z - Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PRPH_OUT_11 [2025-03-24 15:45:46 -0400] 490 Bytes | 139 tokens | Cum: 1852 tkns (23.15% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Rare Stock Picks In May 2024 - From 29 Discerning Analysts**Date: Unknown DateSource: Unknown SourceURL: https://seekingalpha.com/article/4697541-rare-stock-picks-in-may-2024-from-29-discerning-analystsIn our monthly Rare Stock Picks series, we're highlighting May 2024 investment picks. Click here for the list of May 2024 Buy recommendations.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PRPH_OUT_13 [2025-03-24 15:45:47 -0400] 1127 Bytes | 317 tokens | Cum: 2201 tkns (27.51% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-21 8-K Item 7.01 Regulation FD Disclosure.

A copy of the Companys press release dated February 18, 2025, relating to the announcement described in Item 5.02, is furnished as Exhibit 99.1 to this Form 8-K.

The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not ...

S6 - 2025-01-30 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Common Stock Purchase Agrmt

On January 29, 2025, ProPhase Labs, Inc. (the Company, we, us and our) entered into a common stock purchase agreement (the Purchase Agrmt) with an equity line investor (the Investor), wh...

S7 - 2025-01-23 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On January 16, 2025, ProPhase Labs, Inc. (the Company) entered into a Stock Purchase Agrmt (the Agrmt) with JL Projects, Inc., a Delaware corporation (JL Projects), pursuant to which JL Projects purchased from the Co...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PRPH_OUT_15 [2025-03-24 15:45:52 -0400] 805 Bytes | 203 tokens | Cum: 2406 tkns (30.08% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 7.01 Regulation FD Disclosure.

A copy of the Companys press release dated February 18, 2025, relating to the announcement described in Item 5.02, is furnished as Exhibit 99.1 to this Form 8-K.

The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing....

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PRPH_OUT_17 [2025-03-24 15:46:07 -0400] 4792 Bytes | 1388 tokens | Cum: 3896 tkns (48.70% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| Volume: 2,994,166 | SMA50: -2.14% | Market Cap: 12.59M | Option/Short: Yes / Yes | Sales past 5Y: 120.73% | Sales Surprise: 11.56% |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| Avg Volume: 9.64M | SMA200: -77.35% | Shs Outstand: 29.87M | Short Float: 6.30% | Employees: 113 | EPS Surprise: -12.90% |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| Rel Volume: 0.34 | Perf Week: 6.82% | Shs Float: 26.37M | Short Ratio: 0.17 | Debt/Eq: 0.78 | P/E: - |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| RSI (14): 50.67 | Perf Month: -21.14% | Inst Own: 8.10% | Short Interest: 1.66M | Sales Y/Y TTM: -79.66% | Earnings: Nov 13 BMO |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| ATR (14): 0.08 | Perf Quarter: -39.42% | Insider Own: 11.73% | Beta: -0.49 | ROE: -58.71% | |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| SMA20: 2.60% | Index: - | Insider Trans: 0.00% | Sales Q/Q: -62.39% | ROI: -46.12% | |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

No transactions recorded.

Inside Trans: ProPhase Labs, Inc. (PRPH) by Hollenshead Stuart (Chief Operating Officer) on 2025-02-17
- Option (right to buy): 500000 shares at $0 (D)

Inside Trans: ProPhase Labs, Inc. (PRPH) by GLECKEL LOUIS MD (Unknown Title) on 2025-02-14
- Option (right to buy): 100000 shares at $0 (D)

Inside Trans: ProPhase Labs, Inc. (PRPH) by Hirsch Warren (Unknown Title) on 2025-02-14
- Option (right to buy): 100000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: ProPhase Labs, Inc. Common Stock (DE)
Market Cap: 8396495.999300001
Shares Outstanding: 23874029
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 12753000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -27756000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.413101
Average Volume: 2059865.81
30-Day High: 0.5341
30-Day Low: 0.3088

[Detailed Financials: Q3 2024]
- Total Assets: $91,808,000.0
- Total Liabilities: $53,682,000.0
- Total Equity: $38,126,000.0
- Current Assets: $42,235,000.0
- Current Liabilities: $28,698,000.0

[Income Statement: Q3 2024]
- Revenue: $3,146,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.35

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-1,271,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $93,678,000.0
- Total Liabilities: $49,602,000.0
- Total Equity: $44,076,000.0
- Current Assets: $44,143,000.0
- Current Liabilities: $28,012,000.0

[Income Statement: Q2 2024]
- Revenue: $2,474,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.33

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $629,000
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PRPH_OUT_19 [2025-03-24 15:46:12 -0400] 676 Bytes | 167 tokens | Cum: 4336 tkns (54.20% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PRPH_IN_21 [2025-03-24 15:46:13 -0400] 126 Bytes | 29 tokens | Cum: 4442 tkns (55.53% of 8k)
==========================================================================

====================================
[2025-03-24 12:46:13] # Analysis Completed
Elapsed Time: 38.70 seconds